Computational study of novel inhibitory molecule, 1-(4-((2S, 3S)-3-amino-2-hydroxy-4-phenylbutyl)piperazin-1-yl)-3-phenylurea, with high potential to competitively block ATP binding to the RNA dependent RNA polymerase of SARS-CoV-2 virus. Issue 20 (29th November 2022)

• Record Type: Journal Article
• Authors: Sharma, Prem Prakash; Kumar, Sumit; Srivastava, Sukrit; Srivastava, Mitul; Jee, Babban; Gorobets, Nikolay Yu.; Kumar, Dhruv; Kumar, Mukesh; Asthana, Shailendra; Zhang, Peng; Poonam, ; Zoltner, Martin; Rathi, Brijesh
• Is Part Of: Journal of biomolecular structure & dynamics. Volume 40:Issue 20(2022)
• Page Start: 10162
• Page End: 10180
• Publication Date: 2022-11-29
• Subjects: Piperazine3-Amino-4-phenylbutan-2-ol -- SARS-CoV-2 -- in silico screening -- RNA-dependent RNA polymerase (RdRp); Biomolecules -- Periodicals; Molecular structure -- Periodicals; Molecular Biology -- Periodicals; Biomechanics -- Periodicals; 572
• DOI: 10.1080/07391102.2021.1940281
• Languages: English
• ISSNs: 0739-1102

Abstract

Abstract: For coronaviruses, RNA-dependent RNA polymerase (RdRp) is an essential enzyme that catalyses the replication from RNA template and therefore remains an attractive therapeutic target for anti-COVID drug discovery. In the present study, we performed a comprehensive in silico screening for 16, 776 potential molecules from recently established drug libraries based on two important pharmacophores (3-amino-4-phenylbutan-2-ol and piperazine). Based on initial assessment, 4042 molecules were obtained suitable as drug candidates, which were following Lipinski's rule. Molecular docking implemented for the analysis of molecular interactions narrowed this number of compounds down to 19. Subsequent to screening filtering criteria and considering the critical parameters viz. docking score and MM-GBSA binding free energy, 1-(4-((2 S, 3 S )-3-amino-2-hydroxy-4-phenylbutyl)piperazin-1-yl)-3-phenylurea (compound 1 ) was accomplished to score highest in comparison to the remaining 18 shortlisted drug candidates. Notably, compound 1 displayed higher docking score (−8.069 kcal/mol) and MM-GBSA binding free energy (−49.56 kcal/mol) than the control drug, remdesivir triphosphate, the active form of remdesivir as well as adenosine triphosphate. Furthermore, a molecular dynamics simulation was carried out (100 ns), which substantiated the candidacy of compound 1 as better inhibitor. Overall, our systematic in silico study predicts the potential of compound 1 to exhibit a more favourable specific activity than remdesivir triphosphate. Hence, we suggest compound 1 as a novel potential drug candidate, which should be considered for further exploration and validation of its potential against SARS-CoV-2 in wet lab experimental studies. Communicated by Ramasawamy H. Sarma